---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-051588"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:37:54.066106+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q1 sales $15.9B (+50% YoY); Non-GAAP EPS $2.14; raises full-year guidance

## Summary
- Sales $15.9B, +50% YoY (52% ex-FX); KEYTRUDA $4.8B (+23%), LAGEVRIO contributed $3.2B.
- GAAP EPS $1.70 vs $1.08; Non-GAAP EPS $2.14 vs $1.16, both well above prior year.
- Raises 2022 sales guidance to $56.9-$58.1B (17-19% growth); Non-GAAP EPS guidance $7.24-$7.36.
- JANUVIA/JANUMET sales fell 5% to $1.2B; expect loss of EU/China exclusivity in Q3 2022.
- Pipeline progress: FDA approvals for KEYTRUDA in MSI-H endometrial cancer and Lynparza in adjuvant breast cancer.

## SEC filing metadata
- accession: 0001104659-22-051588
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465922051588/0001104659-22-051588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465922051588/tm2213615d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-051588
- JSON: https://secwatch.observer/filing/0001104659-22-051588.json
- Plain text: https://secwatch.observer/filing/0001104659-22-051588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.